Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | DNM1 | Q05193 | 6/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL593010 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL9486435 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL1042003 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL5933161 | 1.00 | — | — | |
| SCHEMBL5606540 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL9486369 | 1.00 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL5932738 | 0.97 | — | — | |
| SCHEMBL1042256 | 0.80 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL2698662 | 0.80 | TSHR (0.53) | TSHRTHRBALDH1A1DNM1LMNA | |
| SCHEMBL7694903 | 0.76 | TSHR (0.57) | TSHRTHRBALDH1A1DNM1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11357792-B2 | Method of administration and treatment | Dyvve Biosciences, Inc. (US) | 2022-06-14 | — | — | US | claimed |
| US-20070269379-A1 | Penetration Enhancer Combinations for Transdermal Delivery | REGENTS OF THE UNIVERSITY OF CALIFORNIA, THE | 2007-11-22 | — | — | US | claimed |
| EP-1517672-A1 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | NEXMED (HOLDINGS), INC. (US) | 2005-03-30 | — | — | EP | claimed |
| WO-2005009510-A2 | PENETRATION ENHANCER COMBINATIONS FOR TRANSDERMAL DELIVERY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050004226-A1 | Compositions and methods for amelioration of human female sexual dysfunction | NEXMED (HOLDINGS), INC. (US) | 2005-01-06 | — | — | US | claimed |
| EP-1137409-B1 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | NEXMED HOLDINGS INC (US) | 2004-05-06 | — | — | EP | claimed |
| WO-2004004689-A1 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | NEXMED (HOLDINGS), INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-6486207-B2 | TOPICALLY APPLYING COMPRISING A VASOACTIVE AGENT, E.G, PROSTAGLANDIN E1, A POLYMER THICKENER, A LIPOPHILIC COMPONENT, AND A BUFFER SYSTEM WHEREIN THE PH ABOUT 3.0-7.4; INCREASING AROUSAL | NEXMED (HOLDINGS), INC. | 2002-11-26 | — | — | US | claimed |
| US-20020028846-A1 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | NEXMED (HOLDINGS), INC. | 2002-03-07 | — | — | US | claimed |
| EP-1137409-A2 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | Nexmed Holdings, Inc. (US) | 2001-10-04 | — | — | EP | claimed |
| WO-2000033825-A2 | COMPOSITIONS AND METHODS FOR AMELIORATION OF HUMAN FEMALE SEXUAL DYSFUNCTION | NEXMED HOLDINGS, INC. (US) | 2000-06-15 | — | — | WO | claimed |
| US-5804547-A | SUBSTRATE IN FORM OF SHEET CARRYING COLOR CARE COMPOSITION AND FABRIC SOFTENER | THE PROCTER & GAMBLE COMPANY (US) | 1998-09-08 | — | — | US | claimed |
| EP-0789589-A1 | COMPOSITION, DEVICE, AND METHOD FOR ELECTROTRANSPORT AGENT DELIVERY | ALZA CORPORATION (US) | 1997-08-20 | — | — | EP | claimed |
| EP-0754029-A1 | FILM FORMING ANTIPERSPIRANT POLYMERS | THE GILLETTE COMPANY (US) | 1997-01-22 | — | — | EP | claimed |
| WO-1996014869-A1 | COMPOSITION, DEVICE, AND METHOD FOR ELECTROTRANSPORT AGENT DELIVERY | ALZA CORPORATION (US) | 1996-05-23 | — | — | WO | claimed |
| WO-1995027473-A1 | FILM FORMING ANTIPERSPIRANT POLYMERS | THE GILLETTE COMPANY (US) | 1995-10-19 | — | — | WO | claimed |
| EP-0322209-B1 | COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-02-10 | — | — | EP | claimed |
| US-4954339-A | ANTICHOLESTEROL AGENTS, SEQUESTERING | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1990-09-04 | — | — | US | claimed |
| WO-1989005828-A1 | COMPOUNDS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-06-29 | — | — | WO | claimed |
| EP-0322209-A1 | Compounds | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1989-06-28 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004226-A1 | Compositions and methods for amelioration of human female sexual dysfunction | PGF, PTGDR, PLA2G2D | TSHR 4059/4885THRB 4367/4885ALDH1A1 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.